[A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].

Fei-Yan Yang,Hua-Fang Wang,Ling-Hui Xia,Qing-Qing Wang,Chen-Jing Qian,Jing He

Zhongguo shi yan xue ye xue za zhi（2022）

引用 1|浏览2

暂无评分

摘要

In the new drug era, ASCT can increase CR rate and prolong OS of NDMM patients. ASCT patients who are mSMART 3.0 high risk stratification or achieved deep response within 3 months after transplantation have better OS than non-ASCT patients receiving new drug chemotherapy. ASCT and mSMART 3.0 risk stratification are independent prognostic factors for OS in NDMM patients.

查看译文

关键词

autologous hematopoietic stem cell transplantation,multiple myeloma,new drug era,propensity matching analysis,survival time

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要